

Press Release
October 15, 2013
Gothenburg, Sweden

Election committee for Vitrolife AB (publ)

The following people have been appointed as members of Vitrolife's election committee for the Annual General Meeting in 2014:

Patrik Tigerschiöld, representing Bure Equity AB
Thomas Olausson
Martin Lewin, representing Eccenovo AB
Carsten Browall, Chairman of the Board

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife on April 29, 2013.

The Annual General Meeting of Vitrolife AB (publ) will be held on May 5, 2014 in Gothenburg.

Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to Vitrolife AB (publ), Att: Chairman of the Board, Box 9080, 400 92 Gothenburg, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.

Gothenburg, October 15, 2013

VITROLIFE AB (publ)

Contact:

Carsten Browall, Chairman of the Board, phone +46 (0)70 255 65 32
Mikael Engblom, CFO, phone +46 (0)31 721 80 14

Vitrolife is an international medical device Group. The Fertility product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes. Vitrolife has approximately 230 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: +46 31 721 80 00.
Fax: +46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com.

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on October 15, 2013 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.